ライフサイエンスコーパス: chemoembolization

1 noma lesions treated with TACE transarterial chemoembolization .

2 ent orthotopic liver transplantation but not chemoembolization.

3 rcinoma underwent conventional transarterial chemoembolization.

4 s for treatment of HCC via drug-eluting bead chemoembolization.

5 disease > 3 cm in diameter is Transarterial Chemoembolization.

6 ns of existing microrobots and current liver chemoembolization.

7 local interventions, including transarterial chemoembolization.

8 prognostic factors affecting survival after chemoembolization.

9 een after thermal ablation and transarterial chemoembolization.

10 an intraprocedural imaging biomarker during chemoembolization.

11 ing findings of ablation after transarterial chemoembolization.

12 r time-to-progression and less toxicity than chemoembolization.

13 was longer following radioembolization than chemoembolization (13.3 months vs 8.4 months, respective

14 val was similar between groups that received chemoembolization (17.5 months) and radioembolization (1

15 oing surgical resection (16%), transarterial chemoembolization (19%), or radiotherapy (14%) and inter

16 ion, 9% versus 0%; resection, 20% versus 3%; chemoembolization, 23% versus 1%; external radiotherapy

17 ization had a higher response rate than with chemoembolization (49% vs 36%, respectively, P = .104).

18 11.1%), ablation alone (7.9%), transarterial chemoembolization (9.5%), and whole-liver irradiation (2

19 ety, and treatment effectiveness of ablative chemoembolization (ACE) in the treatment of hepatocellul

20 I therapies were combined with transarterial chemoembolization, although data regarding the impact on

21 and analyzed data from 245 (122 who received chemoembolization and 123 who received radioembolization

22 , extracellular matrix synthesis inhibitors, chemoembolization and cellular efflux pump inhibition.

23 ellular carcinoma treated with transarterial chemoembolization and includes 377 handcrafted liver tum

24 treated with locoregional therapies (LRTs) (chemoembolization and radioembolization).

25 and 55 (70%) of 78 of patients treated with chemoembolization and radioembolization, respectively (P

26 lly invasive therapies such as transarterial chemoembolization and radiofrequency ablation are used f

27 gnosis, and proven efficacy of transarterial chemoembolization and sorafenib as palliative therapy ha

28 aprocedural tumor perfusion reduction during chemoembolization and TFS and suggests the utility of TR

29 tage perfusion reduction in the tumor during chemoembolization and TFS by using univariate and multiv

30 staging rate of >80% and similar efficacy of chemoembolization and yttrium-90 radioembolization as th

31 g transplant with preoperative transarterial chemoembolization and/or perioperative systemic chemothe

32 ral retinal artery occlusion, retinoblastoma chemoembolization, and ophthalmic artery aneurysm.

33 artery infusion chemotherapy, transarterial chemoembolization, and radioembolization, as well as int

34 ression on chemotherapy, HAIP, transarterial chemoembolization, and transarterial radioembolization a

35 MR findings following ablation and chemoembolization are also reviewed.

36 rome, tumor burden, and drug-eluting embolic chemoembolization as predictors of protracted recovery b

37 ile of balloon micro-catheter trans-arterial chemoembolization (b-TACE) and drug-eluting-microsphere

38 proaches to prevent recurrence have included chemoembolization before and neoadjuvant therapy after s

39 lications between the patients who underwent chemoembolization before orthotopic liver transplantatio

40 r carcinoma who underwent TACE transarterial chemoembolization before surgery.

41 s with a survival benefit from transarterial chemoembolization before therapy.

42 ient underwent two sessions of transarterial chemoembolization between February 2013 and March 2014 w

43 ed therapies (such as transcatheter arterial chemoembolization, bland embolization, and the most rece

44 -90 microsphere treatment with transarterial chemoembolization by using the Cancer of the Liver Itali

45 ipiodol embolization following transarterial chemoembolization can occur even with small Lipiodol vol

46 omized trial has demonstrated superiority of chemoembolization compared with embolization, and the ro

47 cations of aggressive interventions (hepatic chemoembolization, cryoablation, liver transplantation).

48 Transarterial chemoembolization (cTACE) has been shown to improve surv

49 Conventional transarterial chemoembolization (cTACE) is a guideline-approved image-

50 Conventional transarterial chemoembolization (cTACE) is used to treat patients with

51 CC) is treated by conventional transarterial chemoembolization (cTACE) using cone-beam computed tomog

52 tumors following conventional transarterial chemoembolization (cTACE).

53 CC) who underwent conventional transarterial chemoembolization (cTACE).

54 ort who underwent conventional transarterial chemoembolization (cTACE).

55 ility after drug-eluting beads transarterial chemoembolization (DEB-TACE).

56 Keywords: CT, Chemoembolization, Embolization, Abdomen/GI, Liver Suppl

57 ACE were effective in treating HCC.Keywords: Chemoembolization, Experimental Investigations, Laborato

58 lve women awaited breast biopsy; 42, hepatic chemoembolization for cancer; and 60, uterine fibroid em

59 Patients who underwent chemoembolization for HCC showed a response (with both E

60 ion in a patient who underwent transarterial chemoembolization for hepatocellular carcinoma 9 days pr

61 d receive standard-of-care therapy, that is, chemoembolization for patients with intermediate-stage d

62 Recently, chemoembolization has been shown to prolong survival in

63 termediate-stage cancer and can benefit from chemoembolization if they still have preserved liver fun

64 as well as the use of new techniques such as chemoembolization, immunotherapy, and molecular biology,

65 adequate laboratory parameters who underwent chemoembolization in a combined MR imaging-interventiona

66 chieved higher DS success than transarterial chemoembolization in AC (74% vs. 65%; p <0.001).

67 ttained higher DS success than transarterial chemoembolization in AC.

68 umor feeding vessels for transcatheter liver chemoembolization in vivo.

69 patic metastases does improve survival, that chemoembolization increases the patient population eligi

70 Transarterial chemoembolization is a widely used therapy for the treat

71 Transarterial chemoembolization is accepted therapy for hepatocellular

72 Embolization or chemoembolization is an appropriate modality for some pa

73 Background Lung chemoembolization is an emerging treatment option for lu

74 g beads coated with irinotecan transarterial chemoembolization is associated with high objective resp

75 Chemoembolization is one of several standards of care tr

76 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treatment but is on

77 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treatment, although

78 nical Translation, Molecular Imaging-Cancer, Chemoembolization, Liver (C) RSNA, 2022.

79 multimodal approach combining transarterial chemoembolization, liver resection, radiofrequency ablat

80 The combination of these two therapies, or chemoembolization, may provide additive benefits.

81 sy (mean score, 15; 95% CI: 13, 17), hepatic chemoembolization (mean score, 14; 95% CI: 11, 18), and

82 CI: 45, 50) than did women awaiting hepatic chemoembolization (mean score, 26; 95% CI: 22, 29; P < .

83 The chemoembolization mixture consisted of 100 mg of cisplat

84 When chemoembolization (n = 132) and yttrium-90 radioemboliza

85 nge the use of doxorubicin-eluting beads for chemoembolization of HCC.

86 ine utilization of CBCT during transarterial chemoembolization of liver cancer.

87 and safety of bronchial or pulmonary artery chemoembolization of lung metastases using ethiodized oi

88 and technically feasible for superselective chemoembolization of metastatic colorectal cancer liver

89 of vandetanib-eluting radiopaque bead (VERB) chemoembolization of rabbit liver tumors.

90 After chemoembolization of the liver with doxorubicin (Dox), t

91 d a randomized, controlled trial showed that chemoembolization offers a survival advantage in selecte

92 tive patients with HCC who were treated with chemoembolization or radioembolization between January 2

93 Patients with HCC treated by chemoembolization or radioembolization with Yttrium-90 m

94 d with transarterial locoregional therapies (chemoembolization or radioembolization) over a 9-year pe

95 minase activity were more frequent following chemoembolization (P < .05).

96 e, 18; 95% CI: 16, 19) than those of hepatic chemoembolization patients (mean, 15; 95% CI: 13, 17; P

97 sy patients, 23 (95% CI: 18, 28) for hepatic chemoembolization patients, and 23 (95% CI: 18, 27) for

98 lation, injection of radiolabeled particles, chemoembolization, percutaneous ethanol injection, and c

99 c resonance imaging was evaluated after each chemoembolization procedure according to EASL criteria a

100 After a second chemoembolization procedure, 44% (EASL) and 47% (mRECIST

101 At least two chemoembolization procedures should be performed in the

102 es (+/-standard error of the mean) after two chemoembolization procedures were 39%+/-10, 14%+/-7, and

103 1-, 2-, and 3-year survival rates after two chemoembolization procedures were 49%+/-9, 20%+/-8, and

104 unresectable HCC who underwent at least two chemoembolization procedures were included.

105 , as part of the institutional transarterial chemoembolization protocol).

106 gues, interferon combinations, embolization, chemoembolization, radiotherapy with novel somatostatin

107 ression when used as part of a transarterial chemoembolization regimen for unresectable hepatocellula

108 Post-chemoembolization response was seen in 31% and 64% of pa

109 T (during the first and second transarterial chemoembolization sessions, respectively, as part of the

110 onclusion Vandetanib-eluting radiopaque bead chemoembolization showed a pharmacokinetic advantage ove

111 therapy, with comparison with transarterial chemoembolization (TACE) and high-intensity focused ultr

112 nt future liver remnant (FLR), transarterial chemoembolization (TACE) and portal vein embolization (P

113 e unsuitable or refractory to trans-arterial chemoembolization (TACE) and stereotactic body radiother

114 To assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tum

115 ent with transarterial embolization (TAE) or chemoembolization (TACE) between April 2006 and December

116 luding receipt of sorafenib or transarterial chemoembolization (TACE) by HCC-associated comorbidities

117 diation segmentectomy (RS) and transarterial chemoembolization (TACE) combined with microwave ablatio

118 Despite transarterial chemoembolization (TACE) for hepatocellular carcinoma (H

119 ndrome (PES) following transarterial hepatic chemoembolization (TACE) for hepatocellular carcinoma.

120 tion, and 18 were managed with transarterial chemoembolization (TACE) frequently (n = 11) in addition

121 Lipiodol-based transarterial chemoembolization (TACE) has been performed for over 3 d

122 n of residual viable HCC after transarterial chemoembolization (TACE) in a prospective multicenter tr

123 ansarterial embolization (TAE)/transarterial chemoembolization (TACE) in a state of cell cycle arrest

124 monitoring is essential after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HC

125 TARE was compared with transarterial chemoembolization (TACE) in nine studies or sorafenib (n

126 decision for retreatment with transarterial chemoembolization (TACE) in patients with hepatocellular

127 comes of HDR brachytherapy and transarterial chemoembolization (TACE) in patients with unresectable H

128 ltrasound (HIFU) combined with transarterial chemoembolization (TACE) in treating pediatric hepatobla

129 Trans-hepatic arterial chemoembolization (TACE) is a treatment option for liver

130 Transarterial chemoembolization (TACE) is an image-guided minimally in

131 Trans-arterial chemoembolization (TACE) is an important yet variably ef

132 Transcatheter arterial chemoembolization (TACE) is currently considered a first

133 Transarterial chemoembolization (TACE) is currently recommended for un

134 Transcatheter arterial chemoembolization (TACE) is the first-line therapy recom

135 Transarterial chemoembolization (TACE) is the main treatment for inter

136 Background Transarterial chemoembolization (TACE) is the recommended treatment fo

137 Transcatheter arterial chemoembolization (TACE) is the standard of care for pat

138 iofrequency ablation (RFA) +/- transarterial chemoembolization (TACE) or surgical resection by conduc

139 astases (NELM) after the first transarterial chemoembolization (TACE) procedure.

140 Background Despite transarterial chemoembolization (TACE) serving as the first-line treat

141 Transarterial chemoembolization (TACE) using lipiodol-based regimens,

142 Despite transarterial chemoembolization (TACE) was recommended as first line t

143 Transarterial chemoembolization (TACE) was similarly applied to the tw

144 Idarubicin-loaded beads for transarterial chemoembolization (TACE) were previously evaluated for t

145 afety and efficacy of combined transarterial chemoembolization (TACE) with doxorubicin-eluting beads

146 ntration (ITSC) after transcatheter arterial chemoembolization (TACE) with two different sizes of sun

147 ts, six underwent conventional transarterial chemoembolization (TACE), four underwent conventional TA

148 ompare tolerability of SRFA to transarterial chemoembolization (TACE), hepatic resection (HR) and che

149 pes and response to sorafenib, transarterial chemoembolization (TACE), immune checkpoint inhibitor (I

150 ts in different outcomes after transarterial chemoembolization (TACE).

151 advanced-stage HCC to undergo transarterial chemoembolization (TACE).

152 al changes in the tumor after trans-arterial chemoembolization (TACE).

153 arterial embolization (TAE) or transarterial chemoembolization (TACE).

154 10, and absence of neoadjuvant transarterial chemoembolization (TACE).

155 after drug-eluting bead (DEB) transarterial chemoembolization (TACE).

156 r carcinoma (HCC) treated with transarterial chemoembolization (TACE).

157 oil for improved photothermal ablation (PTA)-chemoembolization therapy (CET) of hepatocellular carcin

158 tion, radiofrequency ablation, transarterial chemoembolization, transarterial chemoinfusion, yttrium-

159 Therapies included transcatheter arterial chemoembolization, transarterial radioembolization, abla

160 lar carcinoma (HCC), including transarterial chemoembolization, transarterial radioembolization, and

161 Survival from the time of first chemoembolization treatment was calculated.

162 CIST) and improved survival after the second chemoembolization treatment.

163 f embolization using microspheres alone with chemoembolization using doxorubicin-eluting microspheres

164 ior tumor control and survival compared with chemoembolization using drug-eluting beads in selected p

165 ivo validation of microrobot system-mediated chemoembolization was demonstrated in a rat liver with a

166 phic findings, bronchial or pulmonary artery chemoembolization was performed using an ethiodized oil

167 No response to initial chemoembolization was seen in 43% and 50% of patients ac

168 d by tumor biology and background cirrhosis; chemoembolization was shown to be a safe and effective t

169 Conclusion Lung chemoembolization was technically successful for the tre

170 dical therapies, compared with transarterial chemoembolization, was substantial (5-year survival prob

171 reduction groups at 1, 2, and 5 years after chemoembolization were 66.4%, 42.2%, and 28.2% versus 33

172 Imaging characteristics following chemoembolization were evaluated to determine response r

173 Tumor perfusion changes during chemoembolization were measured by using TRIP MR imaging

174 d seventy-two patients with HCC treated with chemoembolization were studied retrospectively in an ins

175 Background Transarterial chemoembolization with cytotoxic drugs is standard treat

176 Improvements in chemoembolization with drug eluting beads appear promisi

177 ma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads (DEB-TACE).

178 Patients received subselective arterial chemoembolization with mitomycin C, doxorubicin, and cis

179 , intraarterial chemoinfusion, transarterial chemoembolization with or without drug-eluting beads, an

180 ate the safety and efficacy of transarterial chemoembolization with radio-paque doxorubicin-loaded mi